113-07-5
Chemical Structure
Doxapram hydrochloride
- CAS No.: 113-07-5
- Formula:C24H31ClN2O2
- Molecular Weight:414.97
IUPAC Name: 1-ethyl-4-(2-morpholinoethyl)-3,3-diphenylpyrrolidin-2-one hydrochloride
InChIKey: MBGXILHMHYLZJT-UHFFFAOYSA-N
SMILES: O=C1N(CC(C1(C2=CC=CC=C2)C3=CC=CC=C3)CCN4CCOCC4)CC.Cl
Biological Activity: Doxapram (hydrochloride) is a ventilatory stimulant. Doxapram (hydrochloride) inhibits TASK Tandem Pore (K2P) potassium channel function. Doxapram (hydrochloride) inhibits TASK-1 and TASK-3 with an EC50 values of 410 and 37 nM, respectively. Doxapram (hydrochloride) inhibits TASK-1/TASK-3 heterodimeric channel function with an EC50 value of 9 μM. Doxapram (hydrochloride) can be studied in research on apnea in preterm infants[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Doxapram hydrochloride | 99.83% | Doxapram (hydrochloride) is a ventilatory stimulant. Doxapram (hydrochloride) inhibits TASK Tandem Pore (K2P) potassium channel function. Doxapram (hydrochloride) inhibits TASK-1 and TASK-3 with an EC50 values of 410 and 37 nM, respectively. Doxapram (hydrochloride) inhibits TASK-1/TASK-3 heterodimeric channel function with an EC50 value of 9 μM. Doxapram (hydrochloride) can be studied in research on apnea in preterm infants. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Doxapram-d5 hydrochloride | 99.0% | Doxapram-d5 hydrochloride is deuterium labeled Doxapram hydrochloride. Doxapram hydrochloride is a respiratory stimulant. Doxapram hydrochloride increases breathing rate and depth by acting on the brain's respiratory centers and peripheral chemoreceptors. Doxapram hydrochloride inhibits TASK-1, TASK-3, TASK-1/TASK-3 heterodimeric channel function with EC50s of 410 nM, 37 μM, 9 μM, respectively. Doxapram hydrochloride inhibits the Ca²⁺-activated potassium current (IC50 ≈ 13 μM) and Ca²⁺-independent potassium current (IC50 ≈ 20 μM) in type I cells of the carotid body. Doxapram hydrochloride significantly prolongs the effective refractory period of the atrium and has an anti-arrhythmic effect. Doxapram hydrochloride can be used for the study of respiratory depression such as post-anesthesia respiratory depression, chronic obstructive pulmonary disease and apnea of prematurity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Cotten JF, et al., The ventilatory stimulant doxapram inhibits TASK tandem pore (K2P) potassium channel function but does not affect minimum alveolar anesthetic concentration. Anesth Analg. 2006 Mar;102(3):779-85. [Content Brief]
- [2]. Henderson-Smart D, et al., Doxapram treatment for apnea in preterm infants. Cochrane Database Syst Rev. 2004 Oct 18;2004(4):CD000074. [Content Brief]
